Provides exemptions from sales and use tax levied for certain VEGF inhibitors and certain complex biologics. (7/1/13) (OR -$5,000,000 LF RV See Note)
Impact
The implementation of SB 102 is expected to have a significant impact on state laws concerning tax exemptions related to healthcare products. As it stands, the bill will exempt VEGF inhibitors and complex biologics from sales and use tax for all political subdivisions within Louisiana, although it postpones the exemption for local authorities such as parish governing bodies and school boards until after July 1, 2014. This delay gives local entities time to adjust to potential revenue changes stemming from the exemption.
Summary
Senate Bill 102, introduced by Senator Buffington, aims to provide tax exemptions from sales and use taxes for specific medical products, specifically vaso-endothelial growth factor (VEGF) inhibitors and certain complex biologics like monoclonal antibodies. The bill intends to alleviate the financial burden associated with these medications, which are often critical to patients suffering from various serious health conditions. If passed, this exemption would offer widespread relief to those relying on these particular treatments and contribute to reduced healthcare costs for affected individuals.
Sentiment
The general sentiment surrounding SB 102 appears to be positive, particularly among those advocating for healthcare accessibility. Supporters believe that removing sales and use tax on essential medications can make treatments more affordable for patients. However, there may be concerns among local governments regarding potential revenue losses due to these exemptions, which could lead to increased scrutiny and debate about the sustainability of such fiscal decisions.
Contention
Notable points of contention could arise from the potential financial implications of the bill on county and parish revenues, especially given the delayed implementation of tax exemptions for local governing entities. Critics may argue that while the intent of the bill is sound, the economic impact on local budgets could lead to reductions in funding for essential services. These discussions highlight a broader tension between the need to support healthcare affordability and the fiscal responsibilities of local authorities.
Provides for a state sales and use tax exemption for certain transactions related to certain inhibitors and certain complex biologics. (7/1/11) (OR -$4,800,000 LF RV See Note)
Phases in an exemption from local sales tax on certain inhibitors and complex biologics if the Revenue Estimating Conference estimates a certain percentage increase in state general sales tax. (7/1/13) (OR -$5,000,000 LF RV See Note)
Phases in an exemption from local sales tax on certain inhibitors and complex biologics if the Revenue Estimating Conference estimates a certain percentage increase in state general sales tax. (7/1/12) (RE -$5,000,000 LF RV See Note)
Provides for the rate of the state sales and use tax and for exemptions, exclusions, credits, and rebates claimed against sales and use taxes; and provides for a flat rate of income tax for individuals, estates, and trusts, increases the standard deduction, and modifies or repeals certain income tax deductions and credits (Items #5, 6, and 8) (EN SEE FISC NOTE RV See Note)
Provides for certain tax authorities to grant an exclusion from sales tax for repairs to certain property which is delivered out of state. (7/1/13) (EN SEE FISC NOTE LF RV)